An Overview Of Drugs Taken During Pregnancy And Its Outcome
DOI:
https://doi.org/10.37506/t6zw9c70Keywords:
Pregnancy ,Medicine ,Fetus ,Teratogenecity.Abstract
Aim is to create awareness among the women of reproductive age group about the risks associated with consumption of drugs during pregnancy . More than 90% of pregnant women take prescription or non-prescription drugs at some time during pregnancy .In general ,unless absolutely necessary ,drugs should not be used during pregnancy because many of them are harmful to the fetus .Pregnancy introduces unique considerations for drug treatment due to its impact on the pharmacokinetics of medications and the potential harm certain drugs can pose to the fetus. While completely avoiding pharmacological treatment in pregnancy is impractical and risky, as some women have pre-existing medical conditions or develop new ones requiring medication, the challenge lies in balancing effective treatment with fetalsafety. Historical incidents, such as thalidomide in the 1960s, highlighted the risks, but it's crucial to note that congenital abnormalities from teratogenic drugs constitute less than 1% of total cases.To address these concerns, the Food and Drug Administration (FDA) established a system in 1979 for assessing the teratogenic risk of drugs. This classification, ranging from Category A (considered safest) to Category X (absolutely contraindicated in pregnancy), helps guide clinicians in making informed therapeutic decisions. The article delves into various aspects of drug use during pregnancy, emphasizing the importance of weighing risks and benefits to ensure optimal maternal health while safeguarding the developing fetus.
References
Bhide PG. Dopamine, cocaine and the development of cerebral cortical cytoarchitecture: a review of current concepts. Semin Cell Dev Biol 2009; 20: 395–402.
Bonnin A, Levitt P. Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain. Neuroscience 2011; 197: 1–7.
Frederick AL, Stanwood GD. Drugs, biogenic amine targets and the developing brain. Dev Neurosci 2009; 31: 7–22.
Hohmann CF. A morphogenetic role for acetylcholine in mouse cerebral neocortex. NeurosciBiobehav Rev 2003; 27: 351–363.
Kater SB, Lipton SA. Neurotransmitter regulation of neuronal outgrowth, plasticity and survival in the year 2001. Trends Neurosci 1995; 18: 71–72.
Money KM, Stanwood GD. Developmental origins of brain disorders: roles for dopamine. Front Cell Neurosci 2013; 7: 260.
Stanwood GD, Levitt P. Drug exposure early in life: functional repercussions of changing neuropharmacology during sensitive periods of brain development. CurrOpinPharmacol 2004; 4: 65–71.
Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings. Administration, S. A. a. M. H. S: Rockville, MD.
Sundelin Wahlsten V, Sarman I. Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediatr 2013; 102: 544–549.
Killinger CE, Robinson S, Stanwood GD. Subtle biobehavioral effects produced by paternal cocaine exposure. Synapse 2012; 66: 902–908.
Rodgers AB, Morgan CP, Bronson SL, Revello S, Bale TL. Paternal stress exposure alters sperm microRNA content and reprograms offspring HPA stress axis regulation. J Neurosci 2013; 33: 9003–9012.
Vassoler FM, White SL, Schmidt HD, Sadri-Vakili G, Pierce RC. Epigenetic inheritance of a cocaine-resistance phenotype. Nat Neurosci 2013; 16: 42–47.
HON Foundation. NHS Choices [Internet] United Nations: Mother and Child Glossary; [updated on 2002 Jul 9].
Moore PJ. Maternal Physiology during Pregnancy. In: De Cherney AH, Pernoll ML, editors. Current obstetrics and gynaecological diagnosis and treatment. 8th ed. New York: McGraw-Hill; 1994. pp. 146–54.
Porter RS, editor. The Merck Manual's Online Medical Library. Whitehouse Station: Merck Research Lab; 2004.
Sorensan MK, Phillips BB, Mutnick AH. Drug use in specific patient populations: Pediatric, Pregnant, Geriatric. In: Shargel L, Mutnick A, editors. Comprehensive Pharmacy Review. 5th ed. Philadelphia: Lippincott William Wilkins; 2004. pp. 673–82.
Yankowitz J, Niebyl JR, editors. Drug therapy in pregnancy. 3rd ed. Philadelphia: Lippincott William Wilkins; 2001.
Sharma R, Kapoor B, Verma U. Drug utilization pattern during pregnancy in North India. J Med Sci. 2006;60:277–87.
Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, et al. Prescription drug use in pregnancy. Am J ObstetGynaecol. 2004;191:398–407.
Yaffe SJ, editor. Drugs in pregnancy and lactation. 6th ed. Philadelphia: Lippincott William Wilkins; 2002.
Splinter MY, Sagraves R. Prenatal use of medications by women giving birth at a university hospital. South Med J. 1997;90:498–502.
De Jong LT, Van den Berg PB. A study of drug utilization during pregnancy in the light of known risks. Int J Risk Safety Med. 1990;1:91–105.
Pangle BL. Drugs in Pregnancy and Lactation. In: Herfindal ET, Gourley DR, editors. Text book of Therapeutics, Drug and Disease Management. 8th ed. Philadelphia: Lippincott William Wilkins; 2006. pp. 434–48.
Bower C, Elliot EJ. Report to the Australian Government Department of Health: Australian Guide to the diagnosis of Fetal Alcohol Spectrum Disorder (FASD). s.l. : Australian Government , 2016.
Briggs GG. Drug effects on the fetus and breastfed infants. Clin Obstet Gynaecol. 2002;45:6–21.
Lewes L. Which medications are safe in pregnancy? Patient Care. 2000;34:19.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Chinmoyee Deori, Sahid Aziz, Pallavi Bordoloi, Swarnamoni Das
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
https://creativecommons.org/licenses/by-nc/2.0/deed.en